Armune BioScience

Armune BioScience develops and commercializes molecular diagnostic and prognostic tests for prostate, lung and breast cancers.

Armune BioScience, Inc. will develop and commercialize molecular diagnostic and prognostic tests for prostate, lung and breast cancers that will allow physicians and patients to make more personalized treatment decisions. The company was founded by members of the Apjohn Group, LLC, a business accelerator that brings together valuable resources of management talent and angel/seed financing. Armune's technology is based on research performed at the University of Michigan under Dr. Arul Chinnaiyan's direction and published in the New England Journal of Medicine (NEJM 2005; 353:1224-1235), and the work done and published by Dr. David Beer, also at the University of Michigan (Cancer Res 2007;67(7):3461–7). Armune has secured an exclusive license from the University of Michigan for this technology.